NVO Share Price

Open 41.54 Change Price %
High 41.71 1 Day 0.19 0.46
Low 41.42 1 Week 1.23 3.04
Close 41.67 1 Month 4.59 12.38
Volume 2811320 1 Year -14.63 -25.99
52 Week High 57.44
52 Week Low 30.89
NVO Important Levels
Resistance 2 41.94
Resistance 1 41.83
Pivot 41.60
Support 1 41.51
Support 2 41.40
NYSE USA Most Active Stocks
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
SE 40.68 -0.78%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
BAC 23.36 -0.13%
BAC 23.36 -0.13%
BAC 23.36 -0.13%
More..
NYSE USA Top Gainers Stocks
TGI 31.65 30.52%
PBYI 74.95 29.67%
POM 26.93 26.79%
POM 26.93 26.79%
GLF 0.34 25.93%
GLF 0.34 25.93%
TLYS 9.64 12.35%
FNP 35.24 12.02%
FNP 35.24 12.02%
MNI 9.58 9.74%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Novo Nordisk A/S (NYSE: NVO)

NVO Technical Analysis 4
As on 24th May 2017 NVO Share Price closed @ 41.67 and we RECOMMEND Buy for LONG-TERM with Stoploss of 40.35 & Strong Buy for SHORT-TERM with Stoploss of 36.89 we also expect STOCK to react on Following IMPORTANT LEVELS.
NVO Target for May
1st Target up-side 41.43
2nd Target up-side 43.36
3rd Target up-side 45.29
1st Target down-side 35.93
2nd Target down-side 34
3rd Target down-side 32.07
NVO Other Details
Segment EQ
Market Capital 84204396544.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.novonordisk.com
NVO Address
NVO
Novo All
Bagsvaerd, 2880
Denmark
Phone: 45 44 44 88 88
Fax: 45 44 49 05 55
NVO Latest News
Interactive Technical Analysis Chart Novo Nordisk A/S ( NVO NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Novo Nordisk A/S
NVO Business Profile
Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation. The company sells its products primarily in North America, China, Japan, Algeria, Argentina, Australia, Brazil, India, Turkey, and European countries through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.